NanoPass Technologies Ltd. (“NanoPass”), a pioneer in intradermal delivery solutions for immunotherapies, announced recently that it has entered into a clinical supply and support agreement for the supply of MicronJet60, its microneedle delivery device, for use with Immune Design’s oncology immunotherapy products from its ZVex discovery platform.
The agreement will provide Immune Design non-exclusive access and supply for use of the device in all of its relevant cancer immunotherapy programs globally. Financial terms were not disclosed.
Yotam Levin, Chief Executive Officer of NanoPass, said, “We are thrilled about this collaboration with Immune Design, which expands our scope and marks our entry into the growing field of cancer immunotherapy. We believe reliable injection into the skin is critical for successful activation of specific, broad, and effective anti-tumor immune responses.”